vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Loar Holdings Inc. (LOAR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $131.8M, roughly 1.3× Loar Holdings Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 19.3%). Over the past eight quarters, Loar Holdings Inc.'s revenue compounded faster (19.8% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ESPR vs LOAR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $131.8M |
| Net Profit | — | $12.5M |
| Gross Margin | — | 52.1% |
| Operating Margin | 50.6% | 18.0% |
| Net Margin | — | 9.5% |
| Revenue YoY | 143.7% | 19.3% |
| Net Profit YoY | — | 239.5% |
| EPS (diluted) | $0.32 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $131.8M | ||
| Q3 25 | $87.3M | $126.8M | ||
| Q2 25 | $82.4M | $123.1M | ||
| Q1 25 | $65.0M | $114.7M | ||
| Q4 24 | $69.1M | $110.4M | ||
| Q3 24 | $51.6M | $103.5M | ||
| Q2 24 | $73.8M | $97.0M | ||
| Q1 24 | $137.7M | $91.8M |
| Q4 25 | — | $12.5M | ||
| Q3 25 | $-31.3M | $27.6M | ||
| Q2 25 | $-12.7M | $16.7M | ||
| Q1 25 | $-40.5M | $15.3M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | $-29.5M | $8.7M | ||
| Q2 24 | $-61.9M | $7.6M | ||
| Q1 24 | $61.0M | $2.2M |
| Q4 25 | — | 52.1% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 53.8% | ||
| Q1 25 | — | 52.1% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 49.0% | ||
| Q1 24 | — | 48.4% |
| Q4 25 | 50.6% | 18.0% | ||
| Q3 25 | -11.4% | 22.9% | ||
| Q2 25 | 8.6% | 22.2% | ||
| Q1 25 | -34.0% | 22.8% | ||
| Q4 24 | -6.4% | 19.2% | ||
| Q3 24 | -31.0% | 22.1% | ||
| Q2 24 | 3.5% | 22.9% | ||
| Q1 24 | 52.5% | 23.3% |
| Q4 25 | — | 9.5% | ||
| Q3 25 | -35.9% | 21.8% | ||
| Q2 25 | -15.4% | 13.6% | ||
| Q1 25 | -62.2% | 13.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -57.2% | 8.4% | ||
| Q2 24 | -83.9% | 7.9% | ||
| Q1 24 | 44.3% | 2.4% |
| Q4 25 | $0.32 | $0.13 | ||
| Q3 25 | $-0.16 | $0.29 | ||
| Q2 25 | $-0.06 | $0.17 | ||
| Q1 25 | $-0.21 | $0.16 | ||
| Q4 24 | $-0.14 | $-11023.48 | ||
| Q3 24 | $-0.15 | $0.09 | ||
| Q2 24 | $-0.33 | $0.09 | ||
| Q1 24 | $0.34 | $11023.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $84.8M |
| Total DebtLower is stronger | — | $715.7M |
| Stockholders' EquityBook value | $-302.0M | $1.2B |
| Total Assets | $465.9M | $2.0B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $84.8M | ||
| Q3 25 | $92.4M | $99.0M | ||
| Q2 25 | $86.1M | $103.3M | ||
| Q1 25 | $114.6M | $80.5M | ||
| Q4 24 | $144.8M | $54.1M | ||
| Q3 24 | $144.7M | $55.2M | ||
| Q2 24 | $189.3M | $73.2M | ||
| Q1 24 | $226.6M | $28.2M |
| Q4 25 | — | $715.7M | ||
| Q3 25 | — | $279.4M | ||
| Q2 25 | — | $277.7M | ||
| Q1 25 | — | $277.5M | ||
| Q4 24 | — | $277.3M | ||
| Q3 24 | — | $602.1M | ||
| Q2 24 | — | $250.7M | ||
| Q1 24 | — | $534.2M |
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.1B | ||
| Q1 25 | $-426.2M | $1.1B | ||
| Q4 24 | $-388.7M | $1.1B | ||
| Q3 24 | $-370.2M | $769.8M | ||
| Q2 24 | $-344.2M | $758.4M | ||
| Q1 24 | $-294.3M | $420.6M |
| Q4 25 | $465.9M | $2.0B | ||
| Q3 25 | $364.0M | $1.5B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.5B | ||
| Q3 24 | $314.1M | $1.5B | ||
| Q2 24 | $352.3M | $1.1B | ||
| Q1 24 | $373.1M | $1.1B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | — | 1.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $30.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $30.4M | ||
| Q3 25 | $-4.3M | $29.7M | ||
| Q2 25 | $-31.4M | $23.8M | ||
| Q1 25 | $-22.6M | $28.4M | ||
| Q4 24 | $-35.0M | $20.7M | ||
| Q3 24 | $-35.3M | $16.3M | ||
| Q2 24 | $-7.2M | $7.1M | ||
| Q1 24 | $53.8M | $10.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 2.43× | ||
| Q3 25 | — | 1.08× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | — | 5.62× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | 0.88× | 4.81× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
